Clinical Trial Update: (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis [Phase 2]

View source ↗

Summary

The document outlines a Phase 2 clinical trial, PIONEER, evaluating the efficacy and safety of avapritinib versus placebo in patients with indolent systemic mas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Systemic Mastocytosis

Drugs mentioned

• Avapritinib (BLU-285) (avapritinib)

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Indolent Systemic Mastocytosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING